WO2024252182 - CATION EXCHANGE CHROMATOGRAPHY FOR AAV CAPTURE
National phase entry is expected:
Publication Number
WO/2024/252182
Publication Date
12.12.2024
International Application No.
PCT/IB2024/000272
International Filing Date
10.06.2024
Title **
[English]
CATION EXCHANGE CHROMATOGRAPHY FOR AAV CAPTURE
[French]
CHROMATOGRAPHIE PAR ÉCHANGE DE CATIONS POUR CAPTURE DE VAA
Applicants **
MEIRAGTX UK II LIMITED
92 Britannia Walk
London N1 7NQ, GB
Inventors
ABDUR-RAHMAN, Nusaybah
c/o MeiraGTx UK II Limited
92 Britannia Walk
London N1 7NQ, GB
JASULAITYTE, Greta
c/o MeiraGTx UK II Limited
92 Britannia Walk
London N1 7NQ, GB
Priority Data
63/507,072
08.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1620 | |
| EPO | Filing, Examination | 8185 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3510 |
Total: 14476 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides methods for isolating recombinant adeno associated virus (rAAV) vectors, including isolating rAAV full and empty capsids from a mixture of full capsids, empty capsids and host cell impurities, using cation exchange chromatography. The present disclosure also provides a population of rAAV full capsids isolated by the method, and a pharmaceutical composition including the population of full capsids.[French]
La présente divulgation concerne des procédés d'isolement de vecteurs de virus adéno-associés recombinants (VAAr), comprenant l'isolement de capsides pleines et vides de VAAr d'un mélange de capsides pleines, de capsides vides et d'impuretés de cellules hôtes, à l'aide d'une chromatographie par échange de cations. La présente divulgation concerne également une population de capsides pleines de VAAr isolées par le procédé, ainsi qu'une composition pharmaceutique comprenant la population de capsides pleines.